Inserm
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Duchenne muscular dystrophy
FollowWhat is new in Duchenne muscular dystrophy research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- AOC 1044Phase 3 · NCT07587242 · NCT06244082
- delandistrogene moxeparvovecPhase 3 · NCT05967351 · NCT05881408 · NCT06128564 · NCT04626674
- Deramiocel (CAP-1002)Phase 3 · NCT05126758 · NCT04428476
- EteplirsenPhase 3 · NCT03992430
- GivinostatPhase 3 · NCT03373968 · NCT05933057
- PF-06939926Phase 3 · NCT04281485
- SGT-003Phase 3 · NCT06138639 · NCT07160634
- ViltolarsenPhase 3 · NCT04768062
- Zeleciment Rostudirsen (DYNE-251)Phase 3 · NCT07608432
- GNT0004 (1x10e13 vg/kg)Phase 2/3 · NCT07856329
- GNT0004 (3x10e13 vg/kg)Phase 2/3 · NCT07856329
- RGX-202Phase 2/3 · NCT05693142
- BMN 351Phase 2 · NCT07573631 · NCT06280209
- DS-5141bPhase 2 · NCT04433234
- Empagliflozin TabletsPhase 2 · NCT06643442
- ENTR-601-44Phase 2 · NCT07037862 · NCT07682129
- ENTR-601-45Phase 2 · NCT07038824 · NCT07682129
- Givinostat HydrochloridePhase 2 · NCT06769633
- Givinostat Hydrochloride - Cohort 2Phase 2 · NCT06769633
- Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)Phase 2 · NCT06579352
- KER-065Phase 2 · NCT07704099
- NS-089/NCNP-02Phase 2 · NCT05135663 · NCT05996003
- SAT-3247Phase 2 · NCT06867107 · NCT07287189
- SatralizumabPhase 2 · NCT06450639
- SevasemtenPhase 2 · NCT06066580
- Sevasemten Dose 1Phase 2 · NCT05540860 · NCT06100887
- Sevasemten Dose 2Phase 2 · NCT05540860 · NCT06100887
- Sevasemten Dose 3Phase 2 · NCT05540860 · NCT06100887
- Sevasemten Dose 4Phase 2 · NCT05540860
- Sevasemten Dose 5Phase 2 · NCT05540860
- TadalafilPhase 2 · NCT06290713
- TegacoratPhase 2 · NCT07911995
- VM100 Nutritional SupplementPhase 2 · NCT07766980
- WVE-N531Phase 2 · NCT04906460 · NCT07209332
- DYNE-251Phase 1/2 · NCT05524883
- ENTR-601-44 - matching placeboPhase 1/2 · NCT07037862
- ENTR-601-45 - matching placeboPhase 1/2 · NCT07038824
- GNR-097Phase 1/2 · NCT07673809
- NS-050/NCNP-03Phase 1/2 · NCT06053814
- PBGENE-DMD (IV)Phase 1/2 · NCT07429240
- Semaglutide (Rybelsus®)Phase 1/2 · NCT07642635
- SGT-001Phase 1/2 · NCT03368742
- Single dose intravenous of BBM-D101Phase 1/2 · NCT07058662
- INS1201Phase 1 · NCT06817382
- JWK007 Single intravenous infusion administrationPhase 1 · NCT06114056
- MyoPAXonPhase 1 · NCT06692426
- SGLT-2 inhibitorPhase 1 · NCT07172971
- SGLT2 inhibitorPhase 1 · NCT07172971
- SRD-001Phase 1 · NCT06224660
- TacrolimusPhase 1 · NCT06692426
Closest to patients
- Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular DystrophyStudy to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular DystrophyGreat Ormond Street Institute of Child Health · London, United Kingdom + 51 more hospitalsPhase 3Primary completion 2024
- A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular DystrophyA Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular DystrophyCapricor Inc. (sponsor) · 20 hospitals in United StatesPhase 3Primary completion 2025
- Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)Study to Assess the Safety and Efficacy of Viltolarsen in Ambulant Boys With DMD (RACER53-X)Hunan Children's Hospital · Changsha, China + 30 more hospitalsPhase 3Primary completion 2025
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Publication
Cannabidiol-induced Heme oxygenase-1 contributes to modulate the phenotype of hiPSC-derived cardiac fibroblasts from patients with Duchenne muscular dystrophy.
Cannabidiol-induced Heme oxygenase-1 contributes to modulate the phenotype of hiPSC-derived cardiac fibroblasts from patients with Duchenne muscular dystrophy.
Redox biology
PubMed · PMID 42579928Publication
Changes in Bone Parameters and Serum Zinc Levels Following Oral Zinc Supplementation in Duchenne Muscular Dystrophy: A Quasi-Experimental Study.
Changes in Bone Parameters and Serum Zinc Levels Following Oral Zinc Supplementation in Duchenne Muscular Dystrophy: A Quasi-Experimental Study.
International journal of environmental research and public health
PubMed · PMID 42354341Publication
Myostatin inhibition with orally administered Lactobacillus casei expressing a modified human myostatin protein: functional benefits and translational potential in advanced Duchenne muscular dystrophy.
Myostatin inhibition with orally administered Lactobacillus casei expressing a modified human myostatin protein: functional benefits and translational potential in advanced Duchenne muscular dystrophy.
Frontiers in neurology
PubMed · PMID 41607848Publication
Exercise combined with corticoid/omega-3 therapy positively affected skeletal and cardiac muscles in middle aged mdx mice.
Exercise combined with corticoid/omega-3 therapy positively affected skeletal and cardiac muscles in middle aged mdx mice.
International journal of experimental pathology
PubMed · PMID 40308028Review
[Benefits of ω-3 fatty acids in Duchenne muscular dystrophy].
[Benefits of ω-3 fatty acids in Duchenne muscular dystrophy].
Revista medica del Instituto Mexicano del Seguro Social
PubMed · PMID 40489651
Find fellow researchers
Groups with active Duchenne muscular dystrophy work.
Leiden University Medical Center
Leiden, Netherlands
Team details appear once the team leader joins.
Is this your team? Claim it
Newcastle University
Newcastle upon Tyne, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Nationwide Children's Hospital
Columbus, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Agostino Gemelli University Polyclinic
Rome, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
The Ohio State University
Columbus, United States
Team details appear once the team leader joins.
Is this your team? Claim it
National Center of Neurology and Psychiatry
Tokyo, Japan
Team details appear once the team leader joins.
Is this your team? Claim it
University of Florida
Gainesville, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Sorbonne Université
Paris, France
Team details appear once the team leader joins.
Is this your team? Claim it
Sarepta Therapeutics (United States)
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Team details appear once the team leader joins.
Is this your team? Claim it